Fecal Microbiota Transplantation Is Safe for Clostridiodies difficile Infection in Patients with Solid Tumors Undergoing Chemotherapy
- 4 June 2021
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (6) , 2503-2509
Abstract
Background Recurrent Clostridiodies difficile infection (CDI) contributes to morbidity and mortality in cancer patients. Fecal microbiota transplantation (FMT) has been proven to be effective in treatment of recurrent CDI, but immunocompromised patients have been excluded from prospective studies due to safety concerns. The aim of this study was to investigate the safety of FMT for recurrent CDI in immunocompromised patients with solid tumor malignancy undergoing chemotherapy. Methods This was a single center, prospective observational study of patients at a tertiary care cancer center of 10 patients with recurrent CDI who were at least 18 years of age, with a solid tumor malignancy who had received chemotherapy within the previous 6 months. Patients received FMT either by upper endoscopy or colonoscopy and were followed for 6 months. Safety was a primary outcome measured by infections occurring within 2 weeks of FMT. Efficacy of FMT was also evaluated. Results Nineteen patients were evaluated. On applying exclusion criteria, 10 were included in the study. One patient requested to be off study within 2 weeks and was considered a treatment failure. Seven received FMT via upper endoscopy, three via colonoscopy. There were no infectious complications from FMT. Eight patients (80%) were cured after the first FMT. All eight patients went on to restart oncologic treatment with an average of 32.5 days after FMT. Conclusions FMT is safe and effective for recurrent CDI in solid tumor patients undergoing chemotherapy. Patients can resume oncologic treatment after FMT.Keywords
Funding Information
- American Society for Gastrointestinal Endoscopy
- Finch Therapeutics
This publication has 18 references indexed in Scilit:
- Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-AnalysisBlood, 2019
- Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and PreventionClinical Infectious Diseases, 2019
- Clostridium difficileinfection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatmentHospital Practice, 2018
- A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised PatientsCanadian Journal of Gastroenterology and Hepatology, 2018
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)Clinical Infectious Diseases, 2018
- Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United StatesAnnals of Internal Medicine, 2017
- Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infectionAlimentary Pharmacology & Therapeutics, 2015
- Burden ofClostridium difficileInfection in the United StatesNew England Journal of Medicine, 2015
- Duodenal Infusion of Donor Feces for RecurrentClostridium difficileNew England Journal of Medicine, 2013
- Can we identify patients at high risk of recurrent Clostridium difficile infection?Clinical Microbiology and Infection, 2012